17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects
- PMID: 22383500
- PMCID: PMC3359941
- DOI: 10.1164/rccm.201107-1293OC
17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects
Abstract
Rationale: 17β-Estradiol (E2) attenuates hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension (HPH) through an unknown mechanism that may involve estrogen receptors (ER) or E2 conversion to catecholestradiols and methoxyestradiols with previously unrecognized effects on cardiopulmonary vascular remodeling.
Objectives: To determine the mechanism by which E2 exerts protective effects in HPH.
Methods: Male rats were exposed to hypobaric hypoxia while treated with E2 (75 μg/kg/d) or vehicle. Subgroups were cotreated with pharmacologic ER-antagonist or with inhibitors of E2-metabolite conversion. Complementary studies were performed in rats cotreated with selective ERα- or ERβ-antagonist. Hemodynamic and pulmonary artery (PA) and right ventricular (RV) remodeling parameters, including cell proliferation, cell cycle, and autophagy, were measured in vivo and in cultured primary rat PA endothelial cells.
Measurements and main results: E2 significantly attenuated HPH endpoints. Hypoxia increased ERβ but not ERα lung vascular expression. Co-treatment with nonselective ER inhibitor or ERα-specific antagonist rendered hypoxic animals resistant to the beneficial effects of E2 on cardiopulmonary hemodynamics, whereas ERα- and ERβ-specific antagonists opposed the remodeling effects of E2. In contrast, inhibition of E2-metabolite conversion did not abolish E2 protection. E2-treated hypoxic animals exhibited reduced ERK1/2 activation and increased expression of cell-cycle inhibitor p27(Kip1) in lungs and RV, with up-regulation of lung autophagy. E2-induced signaling was recapitulated in hypoxic but not normoxic endothelial cells, and was associated with decreased vascular endothelial growth factor secretion and cell proliferation.
Conclusions: E2 attenuates hemodynamic and remodeling parameters in HPH in an ER-dependent manner, through direct antiproliferative mechanisms on vascular cells, which may provide novel nonhormonal therapeutic targets for HPH.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig1.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig2.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig3.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig4.gif)
![Figure 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig5.gif)
![Figure 6.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig6.gif)
![Figure 7.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig7.gif)
![Figure 8.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig8.gif)
![Figure 9.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig9.gif)
![Figure 10.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig10.gif)
![Figure 11.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3359941/bin/AJRCCM1859965fig11.gif)
Comment in
-
LC3 as a potential therapeutic target in hypoxia-induced pulmonary hypertension.Autophagy. 2012 Jul 1;8(7):1146-7. doi: 10.4161/auto.20520. Epub 2012 May 25. Autophagy. 2012. PMID: 22627195 Free PMC article.
Similar articles
-
Beta-estradiol attenuates hypoxic pulmonary hypertension by stabilizing the expression of p27kip1 in rats.Respir Res. 2010 Dec 24;11(1):182. doi: 10.1186/1465-9921-11-182. Respir Res. 2010. PMID: 21182801 Free PMC article.
-
Hypoxia Upregulates Estrogen Receptor β in Pulmonary Artery Endothelial Cells in a HIF-1α-Dependent Manner.Am J Respir Cell Mol Biol. 2018 Jul;59(1):114-126. doi: 10.1165/rcmb.2017-0167OC. Am J Respir Cell Mol Biol. 2018. PMID: 29394091 Free PMC article.
-
LC3 as a potential therapeutic target in hypoxia-induced pulmonary hypertension.Autophagy. 2012 Jul 1;8(7):1146-7. doi: 10.4161/auto.20520. Epub 2012 May 25. Autophagy. 2012. PMID: 22627195 Free PMC article.
-
Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease.J Cardiovasc Pharmacol. 2010 Dec;56(6):696-708. doi: 10.1097/FJC.0b013e3181f9ea8d. J Cardiovasc Pharmacol. 2010. PMID: 20881610 Free PMC article. Review.
-
A narrative review of research advances in hypoxic pulmonary hypertension.Ann Transl Med. 2022 Feb;10(4):230. doi: 10.21037/atm-22-259. Ann Transl Med. 2022. PMID: 35280399 Free PMC article. Review.
Cited by
-
Exploring the pathogenesis of pulmonary vascular disease.Front Med (Lausanne). 2024 Jul 10;11:1402639. doi: 10.3389/fmed.2024.1402639. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39050536 Free PMC article. Review.
-
Hydroxy-Safflower Yellow A Mitigates Vascular Remodeling in Rat Pulmonary Arterial Hypertension.Drug Des Devel Ther. 2024 Feb 20;18:475-491. doi: 10.2147/DDDT.S439686. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38405578 Free PMC article.
-
Sinus venosus adaptation models prolonged cardiovascular disease and reveals insights into evolutionary transitions of the vertebrate heart.Nat Commun. 2023 Sep 7;14(1):5509. doi: 10.1038/s41467-023-41184-y. Nat Commun. 2023. PMID: 37679366 Free PMC article.
-
Histone lactylation driven by mROS-mediated glycolytic shift promotes hypoxic pulmonary hypertension.J Mol Cell Biol. 2023 Apr 20;14(12):mjac073. doi: 10.1093/jmcb/mjac073. J Mol Cell Biol. 2023. PMID: 36564027 Free PMC article.
-
Biofunctional roles of estrogen in coronavirus disease 2019: Beyond a steroid hormone.Front Pharmacol. 2022 Oct 19;13:1003469. doi: 10.3389/fphar.2022.1003469. eCollection 2022. Front Pharmacol. 2022. PMID: 36339571 Free PMC article. Review.
References
-
- Hoeper MM, Barbera JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54:S85–S96 - PubMed
-
- Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43–S54 - PubMed
-
- Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006;99:675–691 - PubMed
-
- Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013–L1032 - PubMed
-
- Pak O, Aldashev A, Welsh D, Peacock A. The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J 2007;30:364–372 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous